Inhibikase Therapeutics, Inc. (IKT) Press Releases https://www.inhibikase.com/news/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/inhibikase/files/theme/images/logo-sm.png Inhibikase Therapeutics, Inc. Logo https://www.inhibikase.com Equisolve Investor Relations Suite <![CDATA[Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension]]> https://www.inhibikase.com/news/press-releases/detail/140/inhibikase-therapeutics-announces-enrollment-of-first Tue, 07 Apr 26 08:00:00 -0400 https://www.inhibikase.com/news/press-releases/detail/140/inhibikase-therapeutics-announces-enrollment-of-first <![CDATA[Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)]]> https://www.inhibikase.com/news/press-releases/detail/139/inhibikase-therapeutics-announces-inducement-grants-under Fri, 03 Apr 26 14:01:00 -0400 https://www.inhibikase.com/news/press-releases/detail/139/inhibikase-therapeutics-announces-inducement-grants-under <![CDATA[Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity]]> https://www.inhibikase.com/news/press-releases/detail/138/inhibikase-therapeutics-announces-full-year-2025-financial Thu, 26 Mar 26 16:01:00 -0400 https://www.inhibikase.com/news/press-releases/detail/138/inhibikase-therapeutics-announces-full-year-2025-financial <![CDATA[Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants]]> https://www.inhibikase.com/news/press-releases/detail/137/inhibikase-therapeutics-announces-pricing-of-100-million Thu, 20 Nov 25 21:54:00 -0500 https://www.inhibikase.com/news/press-releases/detail/137/inhibikase-therapeutics-announces-pricing-of-100-million <![CDATA[Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants]]> https://www.inhibikase.com/news/press-releases/detail/136/inhibikase-therapeutics-announces-proposed-public-offering Thu, 20 Nov 25 16:12:00 -0500 https://www.inhibikase.com/news/press-releases/detail/136/inhibikase-therapeutics-announces-proposed-public-offering <![CDATA[Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension]]> https://www.inhibikase.com/news/press-releases/detail/135/inhibikase-therapeutics-advancing-ikt-001-to-global-phase-3 Thu, 20 Nov 25 16:01:00 -0500 https://www.inhibikase.com/news/press-releases/detail/135/inhibikase-therapeutics-advancing-ikt-001-to-global-phase-3 <![CDATA[Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity]]> https://www.inhibikase.com/news/press-releases/detail/134/inhibikase-therapeutics-announces-third-quarter-2025 Fri, 14 Nov 25 16:01:00 -0500 https://www.inhibikase.com/news/press-releases/detail/134/inhibikase-therapeutics-announces-third-quarter-2025 <![CDATA[Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer]]> https://www.inhibikase.com/news/press-releases/detail/133/inhibikase-therapeutics-strengthens-leadership-team-with Tue, 19 Aug 25 08:00:00 -0400 https://www.inhibikase.com/news/press-releases/detail/133/inhibikase-therapeutics-strengthens-leadership-team-with <![CDATA[Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity]]> https://www.inhibikase.com/news/press-releases/detail/132/inhibikase-therapeutics-announces-second-quarter2025 Thu, 14 Aug 25 16:50:00 -0400 https://www.inhibikase.com/news/press-releases/detail/132/inhibikase-therapeutics-announces-second-quarter2025 <![CDATA[Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity]]> https://www.inhibikase.com/news/press-releases/detail/131/inhibikase-therapeutics-announces-first-quarter2025 Wed, 14 May 25 16:05:00 -0400 https://www.inhibikase.com/news/press-releases/detail/131/inhibikase-therapeutics-announces-first-quarter2025